This era was marked by the approval of Johnson & Johnson’s (J&J) Remicade (infliximab ... with J&J’s Stelara (ustekinumab) leading the way in 2019. This therapy, initially thought to owe ...

Stelara is predicted to be the ninth best-selling ... including Janssen’s Remicade (infliximab) and Humira, which faced the introduction of biosimilars in Europe in 2018.

Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was highly similar to Stelara. Patients may now switch between Otulfi and ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases.

Extensive analytical characterization between Starjemza and US and EU Stelara was conducted on structural, physicochemical, and biological properties to support bio-similarity of Starjemza. A ...

Extensive analytical characterization between STARJEMZA® and US and EU Stelara® was conducted on structural, physicochemical, and biological properties to support bio-similarity of STARJEMZA®.

a biosimilar referencing Stelara ® (ustekinumab) Injection. STARJEMZA ® is Bio-Thera's third FDA approved product. (PRNewsfoto/Hikma Pharmaceuticals USA Inc.) "This approval and our partnership ...

Ustekinumab offers superior itch relief compared to guselkumab in severe psoriasis, despite guselkumab's better skin lesion improvement. The study involved 108 patients, with 90.4% of ustekinumab ...

a biosimilar referencing Stelara ® (ustekinumab) Injection. STARJEMZA ® is Bio-Thera's third FDA approved product. Bio-Thera and Hikma entered into a license and commercialization agreement for ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative ...